Telix Pharmaceuticals is trading 4.8% down today at $10.32 amid profit-taking and short-term consolidation following a period of strong gains and heightened volatility.
- The decline occurs despite recent positive catalysts, including the FDA's acceptance of the resubmitted TLX101-Px brain cancer imaging NDA.
- No fresh negative company-specific news or regulatory setbacks have emerged, with the company recently opening a new radiopharmaceutical manufacturing facility in Melbourne.